GlassScriptPhysician profile
Seth T Wagner
NPI 1659506277
$2,641.35
in general payments reported to CMS, 2019-2025
32 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $30.74 · 2021: $16.51 · 2022: $412 · 2023: $677 · 2024: $640 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $252.17 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $237.82 | 2022-2025 | |
| Amgen INC. | $207.02 | 2019-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $197.65 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $162.34 | 2019-2025 | Farxiga, Breztri |
| Abbott Laboratories | $135.11 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Abbvie INC. | $110.03 | 2022-2025 | Ubrelvy, Qulipta |
| Dexcom, INC. | $97.45 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $96.11 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.97 | 2022-2024 | Ofev, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $77.13 | 2022 | |
| Xeris Pharmaceuticals, INC. | $62.39 | 2023-2024 | Gvoke Hypopen |
| Medtronic, INC. | $59.50 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Mannkind Corporation | $59.40 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.62 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.41 | 2022-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $40.12 | 2022-2024 | Shingrix |
| Sanofi Pasteur INC. | $31.80 | 2019-2022 | |
| Axsome Therapeutics, INC. | $30.88 | 2025 | Auvelity |
| Shield Therapeutics INC | $24.94 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $23.90 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2022 | |
| Inspire Medical Systems, INC. | $20.44 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $20.25 | 2024 | Voquezna |
| Corcept Therapeutics | $17.80 | 2025 | Korlym |
| Dynavax Technologies Corporation | $17.23 | 2019 | |
| Axonics, INC. | $16.51 | 2021 | |
| Horizon Therapeutics Plc | $15.26 | 2019 | |
| Boston Scientific Corporation | $14.68 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $13.26 | 2022 | |
| Strongbridge US INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.